There has been accelerating progress in the development of retinal prosthesis systems designed to partially restore vision to people with retinitis pigmentosa or macular degeneration. Current retinal prostheses can be divided into two types: those that receive power and information from passive or active photodiodes (optoelectronic systems) and those based on multielectrode arrays powered by cables or transcutaneous telemetry systems. Currently, four research groups have ongoing chronic implantation clinical studies, and two of these groups plan to have commercial retinal prosthesis systems available within the next 2 years. This paper reviews the development and current status of the most significant international retinal prosthesis research groups and discusses future prospects and issues associated with their retinal prosthesis systems.
Introduction
Electrical stimulation of a component of the human visual system can elicit the perception of light spots known as 'phosphenes'. Over the past 30 years, a number of research efforts have aimed to utilise this phenomenon to provide partial restoration of sight to the blind. Earlier research in visual prostheses focussed on surface or penetrating electrode stimulation of the visual cortex; 1,2 however, currently the most active research is in retinal stimulation as treatments for retinitis pigmentosa (RP) and age-related macular degeneration (AMD), both conditions involving degradation of the retinal photoreceptors (although recent drug therapies for AMD, such as Lucentis, might shift the focus of current treatments to RP). In 1956, the Australian researcher Tassicker 3 was the first to patent a method of implanting a light-sensitive selenium photodiode behind a blind person's retina to restore intermittent light sensation. Influenced by the success of the cochlear implant in stimulating secondary neurons to transfer sensory information, early retinal prosthesis researchers examined whether retinocortical connections survived in profoundly blind people. 4 Results from post-mortem examinations of profoundly blind people showed 80% of the inner nuclear layer and approximately 30% of the ganglion cell layer to be spared. 5 For a retinal visual prosthesis to work, there must be some functional retinal ganglion cells (RGCs), and therefore these systems are not capable of treating conditions such as glaucoma and diabetic retinopathy. Prosthesis systems that target the visual cortex, optic nerve, 6 or the dorsal lateral geniculate nucleus of the thalamus 7 may provide solutions for these conditions.
There are considerable challenges to the development of a successful retinal prosthesis. Significant issues include limitations to the number of electrodes, biocompatibility, encapsulation, electrode degradation, power requirements, signal and image processing, interference with residual vision, functional evaluation, and training. Despite these issues, currently, more than 20 different groups (for a recent list see Rizzo et al 8 ) are researching the development of intraocular (subretinal and epiretinal, and suprachoroidal) and extraocular (trans-and episcleral) retinal prostheses.
Optoelectronic approaches
A focus of this review is on optoelectronic prostheses, or systems that involve the direct conversion of energy from light to electricity (typically from photodiode arrays). Generally, the optoelectronic approaches have concentrated on subretinal stimulation, where the implant is located behind the photoreceptor layer and in front of the retinal pigment epithelium. The advantage of this location is that existing information-reduction functions in the inner nuclear layer (amacrine, bipolar, and horizontal cell nuclei) may still be utilised (unlike epiretinal approaches, which are more likely to stimulate the retinal ganglion and amacrine cells directly).
In this section, four systems based primarily on optoelectronic power transfer and at various stages of development are discussed. The first company, Optobionics Corporation, founded in 1990, developed an 'artificial silicon retina' (ASR) consisting of 5000 microelectrode-tipped passive microphotodiodes (powered purely from ambient light). After a number of successful in vitro and in vivo animal trials, Optobionics received approval from the US Food and Drug Administration (FDA) to commence safety and feasibility trials in six patients, and a 2-mm diameter passive multiphotodiode array (MPDA) was implanted in the right eye of six legally blind patients with RP. All patients reported improvements in visual function; however, these were unlikely to have been solely from retinal electrical stimulation, as improvement did not occur immediately but over several weeks and occurred in both stimulated and unstimulated areas of the visual field. Therefore, the ASR appeared to have triggered neurotrophic-type mechanisms in the retina. 9 An involuntary petition to liquidate was filed against Optobionics in 2007.
A Southern German subretinal prosthesis team led by the University Eye Hospital in Tubingen was formed in 1995. Significant early research involved both in vitro and in vivo experiments aimed at determining threshold parameters and surgical techniques. 10 In 2003, the company Retina Implant was formed from this group. As natural photoreceptors are much more efficient than photodiodes, the group chose to install an additional set of photodiodes that are irradiated by infrared light and generate electrical power to supply the amplification circuits in the retinal implant, 11 before developing an active power source (where the photodiodes are modulating current delivered from an external source) (Figure 1 ). In 2006, an active hybrid 1500 microphotodiode array (MPDA) was implanted into the subretinal space of six patients for 30 days (although one patient later refused to have it removed). Two of these patients reported phosphenes through the MPDA, although only when larger areas of the array were illuminated (not for a single photodiode/electrode). In addition to the microphotodiodes, 16 direct stimulation electrodes were also included in the device, which were found to elicit phosphenes in four subjects. Some complications were reported, including mild macular oedema. Perception of phosphenes appeared to rely on stimulation of a three-or four-electrode neighbourhood, 12 which may be due to the interference between on and off receptors during simultaneous stimulation. Retina Implant intends to release a commercial product by the beginning of 2010.
An alternate optoelectronic approach has been developed by Palanker et al 13 at Stanford University. Their proposed system is similar in design to that of Optobionics and the Retina Implant system. The significant difference is the use of goggle-mounted infrared projection system to activate implanted photodiodes ( Figure 2 ). Owing to the transparency of these goggles to normal light, the system could be used to supplement remaining vision with phosphene perception. The system can be used with both subretinal and epiretinal implants. A real-time tracking system is being developed that monitors landmark points on the implanted chip, allowing the image projected from the LCD display to be adjusted to the current position of the chip. Although the implant covers only 101 of the visual field, the projected infrared image corresponds to a larger field of view (301) than most retinal prostheses, and is accessible by eye movements. The system also allows location-dependent image processing. 15 More recently, 14 the use of a laser diode for enhanced brightness of the image-projection system has been described. An additional benefit of the photovoltaic version of the system is that pixels operate independently and they can be placed in different locations within the subretinal space. Charge injection has now been maximised by applying a common bias voltage provided from a gogglemounted radiofrequency coil. To ensure that electrodes are close to target cells, Palanker et al 13 have also developed techniques allowing the retina to migrate very closely to the implant.
Recently, a novel photostimulation approach has been proposed by a group from Imperial College, London, that involves virally re-engineering RGCs and/or bipolar cells to become light sensitive. 16 These cells could then be stimulated to fire action potentials by the use of a headmounted gallium nitride LED array (a similar design to modern virtual reality headsets) ( Figure 3) . A unique feature of this approach is the potential to inhibit as well as excite action potentials. Other advantages include minimal damaging surgery, the lack of an implanted cable or power supply, and the ability to target individual receptive fields and cells. 17 Although in vivo animal studies are planned to commence in the next year, human testing is still some years away. The system will only be useful for people without light perception, as any remaining photoreceptors will be quickly bleached by the high-intensity light.
Alternate preliminary biochemical approaches to retinal prosthetics have also been proposed by Greenbaum et al 18 (where light-absorbing pigments from spinach are added to ganglion or bipolar cells) and Chambers et al 19 (who suggest a ganglion-cell stimulation method based on semisynthetic light-activated ion channels). 
Eye
External power-based approaches to retinal prostheses An alternative to optoelectronic prostheses is the use of implanted multielectrode arrays (MEAs) and transcutaneous telemetry to transfer data and power. An advantage with this approach is that image capture and processing can take place in external, commercially available devices (such as a head-mounted camera linked to a pocket PC) that can be easily upgraded or replaced.
Second
Further study has resulted in a functioning system consisting of a glass-mounted camera and an external image-processing unit connected through a telemetric inductive link to the intraocular unit (containing a power source, signal transceiver, stimulation unit, and electrode array). 21 Between 2002 and 2004, Second Sight conducted acute and chronic testing of a 16-electrode device (the Argus 16). Six subjects with bare light perception secondary to RP were enrolled in this trial and were able to use spatial information from the stimulator to detect motion (such as a bar moving in front of the camera) and distinguish common household objects. 22 Successful in vivo animal studies of the Argus II implant, consisting of 60 independently controllable electrodes, have been reported, and in 2007, the US FDA approved the device for clinical study in humans. 23 Intelligent Medical Implants have also developed an epiretinal 'learning retinal implant system', similar in design to the Second Sight model. The main feature of this system is an 'adaptive retina encoder' developed to assist with the adjustment of stimulation parameters for individual patients. Acute testing has been carried out on 20 subjects with RP, 19 of whom reported small phosphenes with different shapes and in a variety of colours. 24 Chronic testing of the learning retinal implant has also been ongoing since late 2005, although results are unavailable.
The Boston Retinal Implant Project that conducted an important early study on an epiretinal prosthesis, however, later changed their focus to developing a 15-electrode subretinal implant, with most of the device located outside the eye. The use of iridium oxide (rather than platinum) allows smaller electrodes, which in theory are capable of delivering higher levels of charge. Acute studies have been performed successfully with five patients with RP and one sighted patient. 25, 26 A second German epiretinal prosthesis group, Epiret GmbH, has also recently successfully implanted a 25-electrode array (EPIRET3) into six patients over a 4-week period. 23 The implant was tolerated in five eyes with moderate post-operative inflammation, and the position of the implants remained stable until removal. 27 Two Australian research groups are involved in the development of retinal prostheses. The Australian Vision Prosthesis Group (AVPG) has designed an epiretinal prosthesis with a similar design to Second Sight, in which power and data are sent to an intraocular implant through a transcutaneous inductive link. 28 A feature of the implant is the unique hexagonal arrangement of electrodes that can assist the localisation of current spread through the neural retina 29 ( Figure 4) . The AVPG has conducted research into simulation (see below), both internal and external hardware, and animal model experiments. 30 The group aims to commence acute human testing of a suprachoroidal electrode placement within the next 2 years (followed by chronic testing).
The second Australian group, the Australian Bionic Eye Foundation, aims to adapt MEA technology from Cochlear Ltd to stimulate the peripheral retina in patients with RP (aiming to increase the peripheral visual field to assist with orientation and mobility). In an extraocular approach, the group has adapted an 18-electrode brain stem implant to be attached outside the sclera. The advantages of this location are that the macula is not at risk of further damage and intraocular surgery is avoided. An acute study of 17 patients with RP and 15 Eye normally sighted patients has been conducted using contact lens electrodes, and minimum current thresholds for phosphene perception have been identified. 31 A potential disadvantage of the group's approach is the increased distance between electrodes and target neurons, resulting in a lower resolution and high charge required to reach activation thresholds.
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A group from Osaka University, Japan, has also been working towards the development of an extraocular retinal prosthesis, with the anodic-stimulating electrode located in the suprachoroid layer and the cathode located in the vitreous body. The implant was found to generate focal excitation in RGCs in normal animals and in those with degenerated photoreceptors, and thresholds for a safe current have been evaluated. 33 Acute experiments using transcorneal and transscleral simulation in 14 normally sighted and two RP patient volunteers have been performed to obtain threshold parameters. All volunteers reported a round-shaped phosphene in response to transscleral stimulation, and phosphene brightness could be controlled with changes in pulse frequency. 34 As with the Australian Bionic Eye Foundation device, the separation of neural cells from electrodes may cause problems due to overheating, crosstalk, and electrochemical erosion, 13 which may restrict the potential visual acuity of the suprachoroidaltransretinal approach. However, the study by Wong et al 35 in cats using suprachoroidal electrode placement has demonstrated the generation of localised phosphene responses with appropriate electrode configurations.
Image-processing and simulation research
Most of the systems described require an external camera for image acquisition. Apart from the real-time subsampling and conversion of these images to electrode-stimulation patterns, adaptive image processing will probably be required to adjust the resolution, contrast, and brightness of captured images. Non-uniform stimulation thresholds may be required due to the uneven thickness or wavy structure of a diseased retina, 13 and the possibility of continued remodelling of the retina post-implantation could result in spatial corruption and cryptic synapse formation. 36 Epiretinal implants stimulate the RGC layer directly and these cells expect the output from the pre-processed and filtered visual information (from bipolar and amacrine cells), not a camera image. 17 Some of the prosthesis systems discussed aim at replicating these functions (such as the learning retina system from Intelligent Medical Implants and the Stanford University system).
A number of simulation studies have been conducted to determine requirements and limitations of visual prosthesis systems. 43 has been found to be acceptable with a 10 Â 10 array of phosphenes, and the authors noted significant subject-learning effects during trials. In addition, a number of papers have attempted to determine reading requirements. [44] [45] [46] [47] [48] There has been considerable research in image-processing algorithms to assist the visually impaired, which could be integrated into visual prosthesis systems.
As most systems use a head-mounted camera, increased head movements are required to direct gaze and to scan visual scenes. The use of increased head movements by cortical implant recipients was noted by Dobelle. 2 Head scanning has been investigated by Chen et al 49 who suggest that scanning can be used to increase spatial frequency through temporal integration.
Future prospects
The prospects for retinal prostheses in restoring some visual substitution to those blinded by RP or AMD in general appear promising. As a number of companies are competing to produce a commercial visual prosthesis, bias in reported findings has been noted. 23 Three companies aim to release commercial devices before the end of 2010: Second Sight, Intelligent Medical Implants, and Retina Implant.
In the short term, microelectrode array systems (particularly Second Sight) appear to hold an advantage. The main limitation with the Second Sight system appears to be spatial resolution, which could be improved with an increase of stimulating electrodes. However, this increase is constrained by increased safety concerns, the potential for cross-talk, and increased power requirements. 50 Hermetic encapsulation is also a concern for all intraocular devices.
Three epiretinal companies have ongoing clinical studies with chronic implantation: Second Sight, Intelligent Medical Implants, and EpiRet Gmbh. Passive MPDA devices (as used by Optobionics) appear to have failed. Active MPDAs show more promise, and Retina Implant is currently the only subretinal prosthesis to have chronic clinical trials. Three different groups (Boston, Osaka University, and the Australian Bionic Eye Foundation) have completed acute clinical studies.
The biochemical retinal prosthesis approaches (such as Imperial College) appear to be at least 5 years away from commercialisation.
In summary, the restoration of some vision using these devices will be a great achievement. However, none of these retinal prosthesis systems will restore anything resembling normal vision in the near future. Current mobility constraints include the narrow field of view (B10 o ) and the need for head-movement scanning (due to the head-mounted camera). As the field matures, interaction with orientation and mobility staff and the development of pre-and post-operative training programmes and functional evaluation measures will become increasingly important.
